Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | CLK3 | P49761 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.43 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427592 | 0.81 | CHEK1 (0.56) | MAPTCHEK1ACHEPDPK1ALK | |
| SCHEMBL12666733 | 0.81 | CHEK1 (0.69) | MAPTCHEK1ACHE | |
| SCHEMBL12501027 | 0.80 | PDPK1 (0.62) | PDPK1IKBKEALK | |
| SCHEMBL12666721 | 0.80 | CHEK1 (0.56) | MAPTCHEK1ACHEALK | |
| SCHEMBL17967605 | 0.78 | MAPT (1.00) | MAPT | |
| SCHEMBL12666260 | 0.78 | CHEK1 (0.66) | CHEK1ACHE | |
| SCHEMBL2215076 | 0.77 | CHEK1 (0.68) | MAPTCHEK1ACHECLK2DYRK1A | |
| SCHEMBL12674281 | 0.77 | CHEK1 (0.64) | MAPTCHEK1ACHEALK | |
| SCHEMBL18452074 | 0.76 | CLK2 (0.52) | MAPTCHEK1CLK2DYRK1ACLK3 | |
| SCHEMBL12666785 | 0.75 | CHEK1 (0.49) | MAPTCHEK1ACHEPDPK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8501765-B2 | Diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | MAPT 4241/4885CHEK1 1/4885ACHE 4058/4885 |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | MAPT 4858/4885CHEK1 207/4885ACHE 1733/4885 |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | MAPT 4858/4885CHEK1 207/4885ACHE 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.